Anixa Biosciences (ANIX) Stock
What Anixa Biosciences's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -10.2x
- Revenue growth
- 0.0%
- Debt / equity
- 0.00x
What Anixa Biosciences's price implies
Anixa Biosciences's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Anixa Biosciences's 10-K filings.
Anixa Biosciences revenue and free cash flow
FY2016–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $512,000 | — | $210,000 | $210,000 | — |
| Net income | -$13M | -$14M | -$10M | -$13M | -$11M |
| Free cash flow | — | — | — | — | — |
| EPS (diluted) | -$0.45 | $0.45 | -$0.32 | -$0.39 | -$0.34 |
| Operating margin | -2,565.6% | — | -5,243.3% | -6,586.2% | — |
Superinvestors who own ANIX
From each investor's latest 13F filing (what a 13F shows). All 2 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Paul Marshall Marshall Wace | Added | $919,332 | 0.00% | Q2 2026 |
| Jim Simons Renaissance Technologies | Trimmed | $166,244 | 0.0% | Q2 2026 |
Anixa Biosciences insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you). Every purchase
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Oct 30, 2026 | Kumar Amit Chief Executive Officer | 5,000 | $3.17 | $15,850 |
| Oct 23, 2026 | H Titterton Lewis Jr Director | 8,000 | $2.98 | $23,840 |
| Oct 22, 2026 | Kumar Amit Chief Executive Officer | 8,000 | $2.72 | $21,760 |
| Sep 30, 2026 | Catelani Michael President, COO, & CFO | 5,500 | $2.84 | $15,620 |
| Sep 24, 2026 | M Baskies Arnold Director | 5,000 | $2.76 | $13,800 |
| Sep 24, 2026 | Kumar Amit Chief Executive Officer | 7,000 | $2.78 | $19,460 |
| Sep 23, 2026 | H Titterton Lewis Jr Director | 49,036 | $2.69 | $131,907 |
| Sep 10, 2026 | Kumar Amit Chief Executive Officer | 5,000 | $2.76 | $13,800 |
| Sep 10, 2026 | Kumar Amit Chief Executive Officer | 3,000 | $2.75 | $8,250 |
| Sep 10, 2026 | H Titterton Lewis Jr Director | 10,000 | $2.73 | $27,300 |
Fundamental grade
Five factors scored 1 to 9 from ANIX's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Anixa Biosciences compares
Anixa Biosciences's revenue growth is higher than 26% of Healthcare companies and 21% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 26% | 21% |
| ROE | 17% | 6% |
Questions about Anixa Biosciences
Are Anixa Biosciences insiders buying the stock?
10 open-market insider purchases of ANIX in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Anixa Biosciences?
2 of the superinvestors Investingly tracks hold ANIX in their latest 13F, including Paul Marshall, Jim Simons.
Companies like Anixa Biosciences
LENZ Therapeutics Inc (LENZ)$110MFoghorn Therapeutics Inc (FHTX)$110MLexaria Bioscience Corp (LEXX)$112MCellectis SA (CLLS)$107MAnavex Life Sciences Corp (AVXL)$107MImmunic Inc (IMUX)$106MOnKure Therapeutics, Inc. (OKUR)$116MVoyager Therapeutics, Inc. (VYGR)$116MTuHURA Biosciences Inc (HURA)$104M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.